
More than half of Germany's medium-sized companies expect an economic downturn next year, according to a survey by the BVMW business association.
Christoph Ahlhaus, the association's chief executive, said on Saturday that "superficial reforms are no longer enough to get Germany back on track."
He said businesses expect the federal government to finally deliver on long-promised structural reforms and concrete relief measures in areas such as bureaucracy, the labour market, taxation and energy costs.
According to the survey, 54% of companies expect an economic slowdown, while only 22% anticipate an upswing. In addition, 42% of respondents said they plan to scale back investment in 2026, the association said.
Medium-sized companies, known as the Mittelstand, form the backbone of Germany's economy and account for a large share of employment and investment.
The German economy contracted in 2023 and 2024, while growth is forecast to be minimal this year and no meaningful recovery is expected in 2026.
The BVMW surveyed more than 1,000 Mittelstand companies in an online poll conducted between December 18 and 23.
LATEST POSTS
- 1
Grasping the Commencement of Criminal Cases: An Extensive Outline - 2
Dominating Capable Mastercard Utilization: Key Contemplations - 3
How Mars 'punches above its weight' to influence Earth's climate - 4
Courageous Climbing: Trails and Stuff for Outside Lovers - 5
6 Solid Moving Administrations for a Calm Movement
Figure out How to Recognize the Right Areas for 5G Pinnacles\
Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
Pick Your #1 Kind Of Treat
Miley Cyrus details her fear of paper, says fiancé Maxx Morando opens their packages outside: 'That's really why I got engaged'
The Force of Care: Living with Goal
Going with Children: Tips for Tranquil Family Get-aways
Dominating the Mastercard Endorsement Cycle: Six Fundamental Stages
Roche breast cancer pill cuts risk of disease recurrence by 30% in trial












